Chlamydia pneumoniae infection and the risk of multiple sclerosis: A meta-analysis

Multiple Sclerosis

Volumn 12, Issue 4, 2006, Pages 397-411

  Bagos, Pantelis G ^a   Nikolopoulos, G ^b   Ioannidis, A ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Centre for Infectious Diseases Control   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chlamydia pneumoniae; Meta analysis; Multiple sclerosis; Random effects

Indexed keywords

BACTERIAL DNA; IMMUNOGLOBULIN;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; RANDOMIZATION; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ANTIBODIES, BACTERIAL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS;

EID: 33746537149     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458506ms1291oa     Document Type: Article

References (87)

1. Cermelli C, Jacobson S. Viruses and multiple sclerosis. Viral Immunol 2000; 13: 255-67.
2. Hafler DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest 1999; 104: 527-29.
3. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993; 6: 382-427.
4. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998; 50: 571-72.
5. Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6-14.
6. Layh-Schmitt G, Bendl C, Hildt U, Dong-Si T, Juttler E, Schnitzler P et al. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Ann Neurol 2000; 47: 652-55.
7. Grimaldi LM, Pincherle A, Martinelli-Boneschi F, Filippi M, Patti F, Reggio A et al. An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. Mult Scler 2003; 9: 467-71.
8. Sotgiu S, Piana A, Pugliatti M, Sotgiu A, Deiana GA, Sgaramella E et al. Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis and neurological controls. Mult Scler 2001; 7: 371-74.
9. Boman J, Roblin PM, Sundstrom P, Sandstrom M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000; 54: 265.
10. Chatzipanagiotou S, Tsakanikas C, Anagnostouli M, Rentzos M, Ioannidis A, Nicolaou C. Detection of Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis by combination of cell culture and PCR: no evidence for possible association. Mol Diagn 2003; 7: 41-43.
11. Numazaki K, Chibar S. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2001; 57: 746.
12. Saiz A, Marcos MA, Graus F, Vidal J, Jimenez de Anta MT. No evidence of CNS infection with Chlamydia pneumoniae in patients with multiple sclerosis. J Neurol 2001; 248: 617-18.
13. Swanborg RH, Whittum-Hudson JA, Hudson AP. Infectious agents and multiple sclerosis - are Chlamydia pneumoniae and human herpes virus 6 involved? J Neuroimmunol 2003; 136: 1-8.
14. Furrows SJ, Hartley JC, Bell J, Silver N, Losseff N, Stevenson S et al. Chlamydophila pneumoniae infection of the central nervous system in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 152-54.
15. Tsai JC, Gilden DH. Chlamydia pneumoniae and multiple sclerosis: no significant association. Trends Microbiol 2001; 9: 152-54.
16. Greenland S. Meta-analysis. In Rothman KJ, Greenland S eds. Modern epidemiology. Lippincott Williams & Wilkins, 1998: 643-73.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
19. Petiti DB. Meta-analysis decision analysis and cost-effectiveness analysis, Volume 24. Oxford University Press, 1994.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
22. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
25. Duval S, Tweedie R. A nonparametric 'trim and fill' method of accounting for publication bias in meta-analysis. JASA 2000; 95: 89-98.
26. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000; 320: 1574-77.
27. Rostasy K, Reiber H, Pohl D, Lange P, Ohlenbusch A, Eiffert H et al. Chlamydia pneumoniae in children with MS: frequency and quantity of intrathecal antibodies. Neurology 2003; 61: 125-28.
28. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-29.
29. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663-82.
30. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73.
31. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53: 207-16.
32. Munger KL, DeLorenze GN, Levin LI, Rubertone MV, Vogelman JH, Peck CA et al. A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology 2004; 62: 1799-803.
33. Bashir K, Kaslow RA. Chlamydia pneumoniae and multiple sclerosis: the latest etiologic candidate. Epidemiology 2003; 14: 133-34.
34. Yao SY, Stratton CW, Mitchell WM, Sriram S. CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens. Neurology 2001; 56: 1168-76.
35. Munger KL, Peeling RW, Hernan MA, Chasan-Taber L, Olek MJ, Hankinson SE et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 2003; 14: 141-47.
36. Villoslada P, Juste C, Tintore M, Llorenc V, Codina G, Pozo-Rosich P et al. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 2003; 60: 1944-48.
37. Kenealy SJ, Pericak-Vance MA, Haines JL. The genetic epidemiology of multiple sclerosis. J Neuroimmunol 2003; 143: 7-12.
38. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002; 58: 136-38.
39. Hauser SL, Goodkin DE. Multiple sclerosis and other demyelinating diseases. In Fauci A, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL et al. eds. Harrison's principle of internal medicine. McGraw Hill, 1998: 2409-18.
40. Ragonese P, Salemi G, D'Amelio M, Gammino M, Aridon P, Savettieri G. Multiple sclerosis in southern Europe: Monreale City, Italy. A twenty-year follow-up incidence and prevalence study. Neuroepidemiology 2004; 23: 306-309.
41. Nicoletti A, Lo Fermo S, Reggio E, Tarantello R, Liberto A, Le Pira F et al. A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily. J Neurol 2005; 252: 921-25.
42. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P. Chlamydia pneumoniae IgG antibody prevalence in south-western and eastern Finland in 1982 and 1987. Int J Epidemiol 1994; 23: 176-84.
43. Koh WP, Taylor MB, Hughes K, Chew SK, Fong CW, Phoon MC et al. Seroprevalence of IgG antibodies against Chlamydia pneumoniae in Chinese, Malays and Asian Indians in Singapore. Int J Epidemiol 2002; 31: 1001-1007.
44. Miyashita N, Niki Y, Nakajima M, Fukano H, Matsushima T. Prevalence of asymptomatic infection with Chlamydia pneumoniae in subjectively healthy adults. Chest 2001; 119: 1416-19.
45. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 1994; 23: 1315-21.
46. von Hertzen L, Surcel HM, Kaprio J, Koskenvuo M, Bloigu A, Leinonen M et al. Immune responses to Chlamydia pneumoniae in twins in relation to gender and smoking. J Med Microbiol 1998; 47: 441-46.
47. Haberbosch W, Jantos C. Chlamydia pneumoniae infection is not an independent risk factor for arterial disease. Herz 2000; 25: 79-83.
48. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Stat Med 2001; 20: 2219-41.
49. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000; 19: 3417-32.
50. Kaufman M, Gaydos CA, Sriram S, Boman J, Tondella ML, Norton HJ. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult Scler 2002; 8: 289-94.
51. Sriram S, Yao SY, Stratton C, Calabresi P, Mitchell W, Ikejima H et al. Comparative study of the presence of Chlamydia pneumoniae in cerebrospinal fluid of patients with clinically definite and monosymptomatic multiple sclerosis. Clin Diagn Lab Immunol 2002; 9: 1332-37.
52. Granieri E, Casetta I, Tola MR, Ferrante P. Multiple sclerosis: infectious hypothesis. Neurol Sci 2001; 22: 179-85.
53. Norman JE, Jr., Kurtzke JF, Beebe GW. Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. J Chronic Dis 1983; 36: 551-59.
54. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin Infect Dis 1995; 21 Suppl 3: S244-52.
55. Stratton CW, Sriram S. Association of Chlamydia pneumoniae with central nervous system disease. Microbes Infect 2003; 5: 1249-53.
56. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-20.
57. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998; 177: 1322-25.
58. Dong-Si T, Weber J, Liu YB, Buhmann C, Bauer H, Bendl C et al. Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. J Neurol 2004; 251: 542-47.
59. Buljevac D, Verkooyen RP, Jacobs BC, Hop W, van der Zwaan LA, van Doorn PA et al. Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients. Ann Neurol 2003; 54: 828-31.
60. Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 360-69.
61. Derfuss T, Gurkov R, Then Bergh F, Goebels N, Hartmann M, Barz C et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 2001; 124: 1325-35.
62. Dong-Si T, Bendl C, Blaas S, Schnitzler P, Ginsbach CG, Grau AJ. Chlamydia pneumoniae is frequently found in cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 2000; 48: 448.
63. Fainardi E, Castellazzi M, Casetta. I, Cultrera R, Vaghi L, Granieri E et al. Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms. J Neurol Sci 2004; 217: 181-88.
64. Gieffers J, Pohl D, Treib J, Dittmann R, Stephan C, Klotz K et al. Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. Ann Neurol 2001; 49: 585-89.
65. Hao Q, Miyashita N, Matsui M, Wang HY, Matsushima T, Saida T. Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis. Mult Scler 2002; 8: 436-40.
66. Krametter D, Niederwieser G, Berghold A, Birnbaum G, Strasser-Fuchs S, Hartung HP et al. Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult Scler 2001; 7: 13-18.
67. Li WP, Ming X, Cook S, Blumberg B, Dowling P. Chlamydia pneumoniae sequence frequently present in both MS and control spinal fluid. Neurology 2000; 54: A165.
68. Morre SA, De Groot CJ, Killestein J, Meijer CJ, Polman CH, Van der Valk P et al. Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients? Ann Neurol 2000; 48: 399.
69. Pucci E, Tans C, Cartechini E, Morelli M, Giuliani G, Clementi M et al. Lack of Chlamydia infection of the central nervous system in multiple sclerosis. Ann Neurol 2000; 48: 399-400.
70. Ke Z, Lu F, Roblin P, Boman J, Hammerschlag MR, Kalman B. Lack of detectable Chlamydia pneumoniae in brain lesions of patients with multiple sclerosis. Ann Neurol 2000; 48: 400.
71. Hammerschlag MR, Ke Z, Lu F, Roblin P, Boman J, Kalman B. Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis? J Clin Microbiol 2000; 38: 4274-76.
72. Poland SD, Rice GPA. Chlamydia pneumoniae and multiple sclerosis. Neurology 2000; 54: A165.
73. Zuzak KB, Theodore M, Kaufman M, Wagar E, Myers L, Quinn TC et al. Lack of detection of Chlamydia pneumoniae by PCR and tissue culture in cerebrospinal fluids from multiple sclerosis patients and controls. In Saikku P ed. Proceedings of the fourth meeting of the European Society for Chlamydia Research. Societa Edtrice Esculapio, 2000: 303.
74. Derfuss T, Gurkov R, Then Bergh F, Hartmann M, Goebels N, Barz C et al. Intrathecal immune response against Chlamydia pneumoniae in multiple sclerosis. Neurology 2001; 56: A451-52.
75. Parratt J, Tavendale R, Parratt D, Swingelr R, O'Riordan J. Does Chlamydia pneumoniae infection occur in multiple sclerosis? A preliminary investigation of cerebrospinal fluid. J Neurol Neurosurg Psychiatry 2000; 69: 422.
76. Tharp A, Yao S, Sriram. S. Immunogold-electron microscopic detection of Chlamydial bodies in CSF sediment of multiple sclerosis patients. Neurology 2001; 56 (suppl 3): A451.
77. Gorham K, Peeling R, Hernan M, Olek M, Hunter D, Ascherio A. Chlamydia pneumoniae serology and risk of multiple sclerosis. Neurology 2001; 56: A451.
78. Pincherle A, Blasi F, Filippi M, Martinelli-Boneschi F, Martinelli V, Patti F et al. Association between Chlamydia pneumoniae infection and clinical activity in multiple sclerosis. Neurology 2001; 56: A450.
79. Krametter D, Niederwieser G, Berghold A, Birnbaum G, Strasser-Fuchs S, Hartung HP et al. Chlamydia pneumoniae-specific humoral immune responses and clinical disease parameters in multiple sclerosis. Ann Neurol 2001; 49: 135.
80. Gutierrez-Fernandez J, Linares-Palomino J, Fernandez-Sanchez F, Guerrero-Fernandez M, Lopez Espada C, Ros-Diez E et al. The presence of anti-Chlamydia pneumoniae antibodies in peripheral vascular and neurological disorders. Rev Neurol 2001; 32: 501-505.
81. Ikejima H, Haranaga S, Takemura H, Kamo T, Takahashi Y, Friedman H et al. PCR-based method for isolation and detection of Chlamydia pneumoniae DNA in cerebrospinal fluids. Clin Diagn Lab Immunol 2001; 8: 499-502.
82. Fernandez F, Gutierrez J, Mendoza J, Linares J, Soto MJ. A new microimmunofluorescence test for the detection of Chlamydia pneumoniae specific antibodies. J Basic Microbiol 2004; 44: 275-79.
83. Derfuss T, Hohlfeld R, Meinl E. Multiple sclerosis. Chlamydia hypothesis in debate. Nervenarzt 2001; 72: 820-23.
84. Swanborg RH, Whittum-Hudson JA, Hudson AP. Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis - a critical review. Microbes Infect 2002; 4: 1327-33.
85. Tondella ML, Galagoda G, Gaydos CA, Boman J. Is Chlamydia pneumoniae present in cerebrospinal fluid of multiple sclerosis patients? Clin Diagn Lab Immunol 2003; 10: 977-78; author reply 978.
86. Hoption Cann SA, van Netten JP, van Netten C. Chlamydia, Rickettsia, and antibiotic treatment of multiple sclerosis. Ann Neurol 2000; 47: 408-409; author reply 409-11.
87. Sriram S. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000; 55: 1423-24.